cis-2,4-Dimethyl-piperidin | 741660-40-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: cis-2,4-Dimethyl-piperidin
• 英文别名: (2R,4R)-2,4-dimethylpiperidine
• CAS: 741660-40-2
• 化学式: C₇H₁₅N
• 分子量: 113.203
• InChiKey: QOZOFODNIBQPGN-RNFRBKRXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  cis-2,4-Dimethyl-piperidin 、 silver nitrate 、 sodium hydroxide 以1%的产率得到
  参考文献：
  名称：

  OGAWA, KEIICHIRO;TAKEUCHI, YOSHITO;SUZUKI, HIROSHI;NOMURA, YUJIRO, J. AMER. CHEM. SOC., 1984, 106, N 4, 831-841

  摘要：

  DOI：
• 作为产物：
  描述：

  2,4-二甲基吡啶 、 sodium ethanolate 生成 cis-2,4-Dimethyl-piperidin
  参考文献：
  名称：

  OGAWA, KEIICHIRO;TAKEUCHI, YOSHITO;SUZUKI, HIROSHI;NOMURA, YUJIRO, J. AMER. CHEM. SOC., 1984, 106, N 4, 831-841

  摘要：

  DOI：

文献信息

• METHODS FOR FORMING SATURATED (HETERO)CYCLIC BORYLATED HYDROCARBONS AND RELATED COMPOUNDS
  申请人：BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY

  公开号：US20180051042A1

  公开（公告）日：2018-02-22

  The disclosure relates to methods for forming at least partially saturated cyclic and heterocyclic borylated hydrocarbons, as well as related compounds, which can be precursor compounds in the synthesis of any of a variety of pharmaceutical or medicinal compounds with a desired structure and/or stereochemistry for drug synthesis or drug candidate evaluation. The methods generally include reduction of an unsaturated cyclic or heterocyclic borylated hydrocarbon having a boron-containing substituent at an sp 2 -carbon, where such reduction converts the sp 2 -carbon to an sp 3 -carbon at the point of attachment of the boron-containing substituent. The methods can exhibit a selectivity for syn-addition during reduction, which can provide stereospecific products, such as when the unsaturated cyclic or heterocyclic reactant is multiply substituted with boron groups and/or other functional groups.

  本发明涉及用于形成至少部分饱和的环状和杂环硼化烃的方法，以及相关的化合物，这些化合物可以是合成多种具有所需结构和/或立体化学的药物或药用化合物的前体化合物。这些方法通常包括将具有sp2碳上含硼取代基的不饱和环状或杂环硼化烃还原，这样的还原将sp2碳转化为与含硼取代基连接点上的sp3碳。这些方法在还原过程中可表现出对顺式加成的选择性，从而可以提供立体特异性产物，例如当不饱和环状或杂环反应物上多元取代硼基团和/或其他功能基团时。
• [EN] FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES<br/>[FR] COMPOSÉS DE PYRIMIDINE FUSIONNÉS ET COMPOSITIONS PHARMACEUTIQUES ASSOCIÉES POUR LE TRAITEMENT DE MALADIES FIBROTIQUES
  申请人：GALAPAGOS NV

  公开号：WO2021032323A1

  公开（公告）日：2021-02-25

  The present invention discloses compounds according to Formula I, wherein A, B, R1, R2, and Cy are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, pain, and/or abnormal angiogenesis associated diseases by administering the compounds of the invention.